- Home
- CGEM vs OBX Comparison
CGEM vs OBX Comparison
Compare CGEM & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | OBX |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CGEM | OBX |
|---|---|---|
| Price | $21.70 | $16.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $30.13 | N/A |
| AVG Volume (30 Days) | ★ 669.2K | 160.7K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $14.57 |
| 52 Week High | $23.19 | $39.00 |
Technical Indicators
Market Signals| Indicator | CGEM | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 65.06 | 33.59 |
| Support Level | $16.40 | $14.57 |
| Resistance Level | N/A | $22.15 |
| Average True Range (ATR) | 1.18 | 3.96 |
| MACD | 0.16 | -0.51 |
| Stochastic Oscillator | 77.80 | 10.72 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.